文献速递神经技术与安全CTMRPET

FDA批准的神经影像人工智能算法的价值主张

Value Proposition of FDA-Approved Artificial Intelligence Algorithms for Neuroimaging.
PubMed 文献 · J Am Coll Radiol · 2023-08-11

本研究从ACR数据科学研究所AI Central数据库提取2008年5月至2022年8月FDA批准的59个神经影像AI算法,分析其开发者网站宣传的价值主张。结果显示最常宣传的价值是改善医疗质量(38/55,69.1%),其次为节省用户时间(24个,43.6%)、降低成本(9个,15.7%)和增加收入(6个,10.9%)。作者结论指出需进一步研究确定这些宣称的价值是否在临床实践中得到证实。

要点

  • FDA批准的59个神经影像AI算法中,24个兼容非增强CT,21个兼容MRI,9个兼容CT灌注。
  • 55个算法网站中38个(69.1%)宣传改善医疗质量,24个(43.6%)宣传节省时间。
  • 26个算法(43.6%)的产品网站展示用户证言宣传技术价值。

核心结论

  • 神经影像AI算法的开发者和供应商宣传了广泛的价值主张,大多数供应商宣称其产品将改善患者护理;需进一步研究确定开发者宣称的价值是否在临床实践中得到证实。

研究设计与样本

  • 从ACR数据科学研究所AI Central数据库提取2008年5月至2022年8月FDA批准的神经影像AI算法列表,收集每个设备的产品信息及开发者网站上宣传的价值信息。

诊断标准与关键数值

  • 共59个AI神经影像算法获FDA批准:24个兼容非增强CT,21个兼容MRI,9个兼容CT灌注,8个兼容CT血管造影,3个兼容MR灌注,2个兼容PET,6个兼容多种成像技术。
  • 55个算法有网站讨论产品价值:38个(69.1%)宣传改善医疗质量,24个(43.6%)宣传节省用户时间,9个(15.7%)宣传降低成本,6个(10.9%)宣传增加收入,26个(43.6%)展示用户证言。

临床应用与阅片要点

  • 原文未据此给出推荐。

局限性

  • 需进一步研究确定开发者宣称的价值是否在临床实践中得到证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: The number of FDA-cleared artificial intelligence (AI) algorithms for neuroimaging has grown in the past decade. The adoption of these algorithms into clinical practice depends largely on whether this technology provides value in the clinical setting. The objective of this study was to analyze trends in FDA-cleared AI algorithms for neuroimaging and understand their value proposition as advertised by the AI developers and vendors.

METHODS: A list of AI algorithms cleared by the FDA for neuroimaging between May 2008 and August 2022 was extracted from the ACR Data Science Institute AI Central database. Product information for each device was collected from the database. For each device, information on the advertised value as presented on the developer's website was collected.

RESULTS: A total of 59 AI neuroimaging algorithms were cleared by the FDA between May 2008 and August 2022. Most of these algorithms (24 of 59) were compatible with noncontrast CT, 21 with MRI, 9 with CT perfusion, 8 with CT angiography, 3 with MR perfusion, and 2 with PET. Six algorithms were compatible with multiple imaging techniques. Of the 59 algorithms, websites were located that discussed the product value for 55 algorithms. The most widely advertised value proposition was improved quality of care (38 of 55 [69.1%]). A total of 24 algorithms (43.6%) proposed saving user time, 9 (15.7%) advertised decreased costs, and 6 (10.9%) described increased revenue. Product websites for 26 algorithms (43.6%) showed user testimonials advertising the value of the technology.

CONCLUSIONS: The results of this study indicate a wide range of value propositions advertised by developers and vendors of AI algorithms for neuroimaging. Most vendors advertised that their products would improve patient care. Further research is necessary to determine whether the value claimed by developers is actually demonstrated in clinical practice.

来源:J Am Coll Radiol,查看原文。版权归原作者所有。

引用

  1. Bajaj S, Khunte M, Moily NS, et al. Value Proposition of FDA-Approved Artificial Intelligence Algorithms for Neuroimaging. J Am Coll Radiol. 2023. PMID: 37574094. doi:10.1016/j.jacr.2023.06.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。